At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACXP Acurx Pharmaceuticals, LLC*
Post-Mkt 01-15 16:06:55 EST
2.69
-0.05
-1.82%
盘后2.69
+0.000.00%
16:00 EST
High2.77Low2.66Vol56.98K
Open2.77D1 Closing2.74Amplitude4.01%
Mkt Cap6.32MTradable Cap5.97MTotal Shares2.35M
T/O153.37KT/O Rate2.57%Tradable Shares2.22M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Acurx Pharmaceuticals and Leiden University Medical Center Secure $375,000 Health~Holland Grant for Antibiotic Research
Reuters  ·  2025-11-18
Acurx Pharmaceuticals and Leiden University Medical Center Secure $375,000 Health~Holland Grant for Antibiotic Research
Acurx Pharma Q3 net loss narrows to $2 mln
Reuters  ·  2025-11-12
Acurx Pharma Q3 net loss narrows to $2 mln
Acurx Pharmaceuticals reports third quarter cash position of $5.9 million
Reuters  ·  2025-11-12
Acurx Pharmaceuticals reports third quarter cash position of $5.9 million
Acurx Pharmaceuticals Q3 EPS $(1.23) Beats $(1.31) Estimate
Benzinga  ·  2025-11-12
Acurx Pharmaceuticals Q3 EPS $(1.23) Beats $(1.31) Estimate
Press Release: Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
Dow Jones  ·  2025-11-12
Press Release: Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  2025-11-12
Calendar of U.S. Earnings Expected in the Week Ahead
Acurx announces publication of results from ibezapolstat study
TIPRANKS  ·  2025-11-10
Acurx announces publication of results from ibezapolstat study
Acurx Reveals Breakthrough DNA pol IIIC Inhibitor Targeting Drug-Resistant Bacteria
Reuters  ·  2025-11-10
Acurx Reveals Breakthrough DNA pol IIIC Inhibitor Targeting Drug-Resistant Bacteria
Acurx Pharmaceuticals Reports Phase 2 Success for Ibezapolstat in C. difficile Treatment
Reuters  ·  2025-11-10
Acurx Pharmaceuticals Reports Phase 2 Success for Ibezapolstat in C. difficile Treatment
Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025
Reuters  ·  2025-10-28
Acurx Pharmaceuticals Unveils New Data on Microbiome-Sparing Antibiotic Ibezapolstat at IDWeek 2025
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
THOMSON REUTERS  ·  2025-10-27
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
Acurx files to sell 585,000 shares of common stock for holders
TIPRANKS  ·  2025-10-21
Acurx files to sell 585,000 shares of common stock for holders
Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics
Reuters  ·  2025-10-09
Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors, Expanding Global Protection for Novel Antibiotics
Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today?
TIPRANKS  ·  2025-10-08
Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today?
Top Premarket Gainers
MT Newswires Live  ·  2025-10-08
Top Premarket Gainers
Acurx Pharmaceuticals Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
Dow Jones  ·  2025-09-30
Acurx Pharmaceuticals Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
Acurx Announces Positive Opinion From Ema on Pediatric Investigation Plan for Ibezapolstat Use in Children With C. Difficile Infection
THOMSON REUTERS  ·  2025-09-30
Acurx Announces Positive Opinion From Ema on Pediatric Investigation Plan for Ibezapolstat Use in Children With C. Difficile Infection
Acurx Pharmaceuticals Receives Positive EMA Opinion on Pediatric Investigation Plan for Ibezapolstat in Children with C. difficile Infection, Advancing Toward Phase 3 Trials
Reuters  ·  2025-09-30
Acurx Pharmaceuticals Receives Positive EMA Opinion on Pediatric Investigation Plan for Ibezapolstat in Children with C. difficile Infection, Advancing Toward Phase 3 Trials
Acurx Pharmaceuticals Increases Authorized Shares to 250 Million
Reuters  ·  2025-09-23
Acurx Pharmaceuticals Increases Authorized Shares to 250 Million
Acurx Pharmaceuticals Expands Media Partnership with New to The Street for Enhanced Investor Engagement
Reuters  ·  2025-09-06
Acurx Pharmaceuticals Expands Media Partnership with New to The Street for Enhanced Investor Engagement

Introduction

Company Name.
Acurx Pharmaceuticals, LLC*
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Issue price:
--